Breaking News

Takeda, Lilly Ordered to Pay $9B in Actos Case

April 9, 2014

Takeda accused of failing to warn users of cancer risk

A federal jury in Lafayette, LA has reached a verdict in a lawsuit accusing Takeda of failing to warn users about research that linked the diabetes drug Actos to an increased risk of bladder cancer.
Takeda was ordered to pay $6 billion in punitive damages and its partner Eli Lilly & Co. was ordered to pay $3 billion. Takeda and Lilly plan to contest the verdict, which is likely to result in reduced fines. Takeda developed and manufactured Actos and Lilly marketed the drug in the U.S. and Canada.
In 2011, the FDA claimed that use of Actos for more than a year may be associated with heightened risk for bladder cancer. At that time, regulators in France and Germany suspended sales of Actos over health concerns.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks